21172-31-6

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
2-(3-(Trifluoromethyl)phenyl)acetaldehyde is used as a chemical intermediate for the synthesis of various pharmaceuticals and agrochemicals. Its unique chemical structure and strong oxidizing properties make it a valuable component in the development of new drugs and pesticides.
Used in Flavor and Fragrance Industry:
In the food and beverage industry, 2-(3-(Trifluoromethyl)phenyl)acetaldehyde is used as a flavor and fragrance ingredient. Its pungent, fruity odor contributes to the creation of various scents and tastes in a wide range of products, enhancing the sensory experience for consumers.
Used in Research and Development:
Due to its unique chemical properties, 2-(3-(Trifluoromethyl)phenyl)acetaldehyde is also utilized in research and development for the exploration of new chemical reactions and the synthesis of novel compounds with potential applications in various industries.
Safety Precautions:
Given its potential health risks, 2-(3-(Trifluoromethyl)phenyl)acetaldehyde should be handled and stored with caution. It is essential to follow proper safety protocols, including wearing appropriate personal protective equipment, to minimize the risk of ingestion, inhalation, or skin absorption. Additionally, it should be stored in a controlled environment to prevent accidental exposure or contamination.

Upstream product

• 402-24-4 3-(trifluoromethyl)styrene 
• 62451-84-7 (3-trifluoromethyl-phenyl)-acetic acid methyl ester 
• 351-35-9 3-(trifluoromethyl)phenylacetic acid 
• 2338-76-3 3-trifluoromethylphenylacetonitrile 
• 705-29-3 3-Trifluoromethylbenzyl chloride 
• 455-01-6 2-[3-(trifluoromethyl)phenyl]ethanol 
• 21172-30-5 m-Trifluormethylphenyl-acetaldehyd-semicarbazon 
• 30934-60-2 2-[(3-trifluoromethyl)benzyl]-1,3-dioxolane 

Downstream Products

• 586961-78-6 1-(3-trifluoromethylphenyl)-5-hexen-2-ol 
• 30934-66-8 1-phenyl-2-<3-(trifluoromethyl)phenyl>-1-ethanone 
• 433230-53-6 (3-{(4R,5S)-2-Acetoxy-4-hydroxy-5-[(E)-(S)-3-hydroxy-4-(3-trifluoromethyl-phenyl)-but-1-enyl]-cyclopent-1-enylsulfanyl}-propylsulfanyl)-acetic acid methyl ester 
• 1580466-00-7 N¹,N¹-dimethyl-N³-(3-(trifluoromethyl)phenethyl)propane-1,3-diamine 
• 1093877-82-7 C₁₈H₁₄F₃N₃OS 
• 1356862-22-0 C₂₅H₃₀F₄N₂O 
• 1190234-54-8 ethyl 5-(trifluoromethyl)-1-(4-{3-[3-(trifluoromethyl)phenyl]prop-1-ene-1-yl}-1,3-thiazol-2-yl)-1H-pyrazole-4-carboxylate 
• 862205-52-5 {4-methyl-2-oxo-1-[2-(3-trifluoromethylphenyl)ethylamino]-1,2-dihydro-pyridin-3-yl}acetic acid methyl ester 
• 63035-57-4 meso-1,4-Bis(3-trifluormethylphenyl)-2,3-butandiol 
• 63035-58-5 1,4-Bis-(3-trifluormethyl-phenyl)-2-butanol 
• 586961-59-3 2-(3-(trifluoromethyl)phenyl)cyclohexan-1-one 
• 586961-57-1 1-(3-trifluoromethylphenyl)-5-hexen-2-one 
• 838826-73-6 1-(3-trifluoromethylphenyl)-6-hepten-2-one 
• 63035-56-3 cis-1,4-Bis-(3-trifluormethylphenyl)-2-buten 

Relevant academic research and scientific papers

PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE

Disclosed are compounds and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof that may cause degradation of various proteins e.g., IKZF2 (Helios). Also disclosed are pharmaceutical compositions containin

Stereoselective synthesis of 3,4-di-substituted mercaptolactones via photoredox-catalyzed radical addition of thiophenols

A visible light mediated radical addition of thiophenols on 4-phenylbut-3-enoic acids to give diastereoselective synthesis of 3,4-disubstituted γ-lactones is reported. The reaction precludes the conventional prerequisite of conjugate addition. Furthermore, the lactones were successfully utilized in the synthesis of γ-ketoamides.

Maleimide-assisted anti-Markovnikov Wacker-type oxidation of vinylarenes using molecular oxygen as a terminal oxidant

Arylacetaldehydes were successfully synthesized by the anti-Markovnikov Wacker-type oxidation of vinylarenes using 1 atm O2 as a terminal oxidant under mild conditions. Electron-deficient alkenes, such as maleic anhydride and maleimides, were effective additives and would operate as ligands to stabilize the Pd(0) species during the reaction.

PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND

There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I'): (in the above-mentioned general formula (I'), W, Y, R2, R3, R4, and Y4 are as described hereinabove), or pharmaceutically acceptable salts thereof.

N-Propynyl analogs of β-phenylethylidenehydrazines: Synthesis and evaluation of effects on glycine, GABA, and monoamine oxidase

A group of β-phenylethylidenehydrazines possessing a variety of substituents (Me, OMe, Cl, F, and CF3) at the ortho-, meta-, or para-positions of the phenyl ring, in conjunction with either a N-bis-(2-propynyl) or a N-mono-(2-propynyl) moiety, were synthesized and compared to the novel neuroprotective drug β-phenylethylidenehydrazine (PEH) with regard to their ability to inhibit the enzymes GABA-transaminase (GABA-T) and monoamine oxidase (MAO)-A and -B in vitro in brain tissue. Two of the analogs synthesized (mono- and bis-N-propynylPEH) were also studied ex vivo in rats to compare their effects to those of PEH with regard to ability to inhibit GABA-T and MAO and to change brain levels of several important amino acids. Unlike PEH, none of the new drugs inhibited GABA-T in vitro at 10 or 100 μM, and all of the drugs (including PEH) were poor inhibitors (at 10 μM) of MAO-A and -B in vitro. The two analogs studied ex vivo inhibited GABA-T to a lesser extent than PEH, unlike PEH that did not elevate brain levels of GABA, and inhibited MAO-A and -B more potently than PEH. Interestingly, unlike PEH, the two analogs caused marked increases in brain levels of glycine; because of the current interest in drugs that increase glycine availability in the brain as potential antipsychotic drugs, these two analogs now warrant further investigation.

Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases

Compositions and methods of using compositions for treatment of inflammatory diseases and immune disorders are provided. Allylamino compounds are disclosed which are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein 1 (VAP-1). The compounds have therapeutic utility in suppressing inflammation and inflammatory responses, and in treatment of several disorders, including multiple sclerosis and stroke.

Activated iodosylbenzene monomer as an ozone equivalent: Oxidative cleavage of carbon-carbon double bonds in the presence of water

Reported here for the first time are the developments of an efficient method for oxidative cleavage of carbon-carbon double bonds yielding carbonyl compounds by using aryl-λ3-iodanes, which involve a combination of iodosylbenzene and HBF4 in the presence of water. The method serves as a safety alternative to ozonolysis. The oxidative cleavage of olefins probably involves the hitherto unknown direct vicinal dihydroxylations of double bonds with aryl-λ3-iodanes and the subsequent oxidative glycol fissions. Cyclic (cyclopentenes, cyclohexenes, etc.) and acyclic olefins are cleaved smoothly under our conditions. In the reaction of electron-deficient styrenes such as m-nitrostyrene, intermediate formation of the corresponding epoxide was detected. A variety of aryloxiranes also undergo an oxidative cleavage of the epoxide rings under our conditions, and aromatic aldehydes were obtained in good yields. Copyright

Design and biological evaluation of phenyl-substituted analogs of β-phenylethylidenehydrazine

β-Phenylethylidenehydrazine (PEH) has been demonstrated previously to be an inhibitor of γ-aminobutyric acid transaminase (GABA-T) and to cause a marked increase in rat brain levels of GABA, a major neurotransmitter. A group of PEH analogs, possessing a variety of substituents (Me, OMe, Cl, F, and CF3) at the 2-, 3-, and 4-positions of the phenyl ring, were synthesized for evaluation as inhibitors of GABA-T. The details of the synthesis and chemical characterization of the analogs are described. Preliminary in vitro screening for GABA-T inhibition showed that all the analogs possessed activity against this enzyme, although substitution of CF3 at the 2- and 4-positions caused reduced activity. One of the drugs, 4-fluoro-β- phenylethylidenehydrazine, was investigated further ex vivo, where it was shown to inhibit GABA-T, elevate brain levels of GABA, and decrease levels of glutamine, similar to the profile observed previously for PEH.

11-Desoxy-16-aryl-ω-tetranorprostaglandins

11-Desoxy-16-aryl-ω-tetranorprostaglandins and various intermediates and processes employed in their preparation are disclosed. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins but they exhibit a greater tissue specificity of action.